BioHealth News Archive
Here’s how an AstraZeneca spinout deal gets done – Baltimore Business Journal
AstraZeneca PLC’s research and development arm MedImmune Inc. spun off a small biotech startup company called Viela Bio. {iframe}https://www.bizjournals.com/baltimore/news/2018/10/30/here-s-how-an-astrazeneca-spinout-deal-gets-done.html{/iframe}
Read More
What’s next for RightEye following FDA approval – Washington Business Journal
Bethesda health tech company RightEye LLC is finally moving beyond the research and development phase. {iframe}https://www.bizjournals.com/washington/news/2018/10/30/righteye-got-its-fda-approval-here-s-what-s-next.html?ana=e_du_prem&s=article_du&ed=2018-10-30&u=fQFLvOpMSMnvK7iAcBsVng0eb45ba2&t=1541423895&j=84729071{/iframe}
Read More
Alexandria Real Estate’s Marcus on Interest Rates, Drug Pricing – Bloomberg
Joel Marcus, chairman at Alexandria Real Estate Equities, discusses the risk of rising interest rates, how government action on drug pricing could impact the…
Read More
TEDCO’s Builder Fund is closing the investment gap for more entrepreneurs – Technical.ly DC
Although we’re told business isn’t personal, the reality is that business is built on relationships. In other words, it’s not what you know, it’s…
Read More
QIAGEN expands QIAGEN Clinical Insight software to support all major sequencing platforms and assay types
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of major enhancements to QIAGEN Clinical Insight (QCI) bioinformatics solutions to deliver…
Read More
CEL-SCI RECEIVES ABOUT $8 MILLION FROM WARRANT EXERCISES
CEL-SCI Corporation (NYSE American: CVM) announced today it has received just under $8 million through the exercise of warrants to purchase shares of the…
Read More
Neuralstem Announces $2.1 Million Registered Direct Offering
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, today announced that it has entered into definitive agreements…
Read More
RegeneRx Partner Updates on Clinical Trials – Oct 29, 2018
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a…
Read More
Biobuzz Directory – Epigenomics AG Obtains CE Mark for Liquid Biopsy Test for Liver Cancer Detection
Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that it has received CE Mark for its blood test to aid in detecting liver cancer…
Read More
Local entrepreneurs enter shark tank at Shore Hatchery – 47abc
The Shore Hatchery here at Salisbury University has become one of the premiere opportunities for local entrepreneurs and Friday over a dozen were making…
Read More
Aledade raises $23 million — again – Washington Business Journal
The new funding includes a $15 million investment from Palo Alto-based Meritech Capital Partners. {iframe}https://www.bizjournals.com/washington/news/2018/10/17/bethesda-health-tech-company-aledade-raises-23.html{/iframe}
Read More
Wound Care Advantage Partners With Tissue Analytics, Combining 17 Years of Clinical Data With AI and 3D Imaging to Improve Patient Outcomes
Wound Care Advantage, a leading provider of management and consulting services for outpatient wound care and hyperbaric medicine programs, today announced a partnership with…
Read More
U.S. Life Science Real Estate Sector Keeps Expanding
A growing seniors population and increasing prevalence of high-cost diseases like diabetes has generated a surge in funding for healthcare research in recent years…
Read More
REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology…
Read More
GSK developing TB vaccine – Livemint
In what can be termed as a milestone in the fight against tuberculosis (TB), a vaccine by pharma major GlaxoSmithKline (GSK) could be the…
Read More